30 completed, 7 terminated, 2 withdrawn, 1 active not recruiting. 22 Phase 3, 5 Phase 4, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 16, Terminated 3, Withdrawn 2, Unknown 1 |
| Phase 4 | 5 | Completed 4, Terminated 1 |
| Not applicable | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow brolucizumab: new trials by email Literature Review of brolucizumab trials Research Report on brolucizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Glycemic Control Combined With Brolucizumab for Diabetic Macular Edema Intensive Glycemic Management, Brolucizumab - Diabetic Macular Edema, Diabetic Retinopathy | Not applicable | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 100 | 2026-11-30 | 2026-11-13 |
| Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. brolucizumab - Diabetic Macular Edema | Phase 4 | Completed | Novartis Pharmaceuticals | 66 | 2024-12-11 | 2026-04-13 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy Brolucizumab Injection [Beovu] - Age-Related Macular Degeneration, Pachychoroid Neovasculopathy | Phase 3 | Unknown | Yeungnam University College of Medicine | 36 | 2023-01-01 | 2023-01-05 |
| Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection Beovu - Diabetic Macular Edema | Completed | Novartis Pharmaceuticals | 222 | 2022-09-02 | 2025-06-13 | |
| Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 4 | Completed | The University of Hong Kong | 30 | 2022-07-25 | 2024-05-08 |
| Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD Aflibercept, Brolucizumab, early treat and extend (T&E) - Wet Age-related Macular Degeneration | Not applicable | Active not recruiting | Berner Augenklinik | 80 | 2022-05-09 | 2025-12-08 |
| Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting Brolucizumab - Neovascular Age-related Macular Degeneration | Terminated | Novartis Pharmaceuticals | 3 | 2022-04-13 | 2025-01-13 | |
| Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice brolucizumab - Neovascular Age-related Macular Degeneration | Terminated | Novartis Pharmaceuticals | 302 | 2021-11-19 | 2024-10-29 | |
| Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. Brolucizumab - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 122 | 2021-10-15 | 2025-05-16 |
| Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion Brolucizumab - Intraocular Inflammation, Retinal Vascular Occlusion | Completed | Novartis Pharmaceuticals | 198 | 2021-08-23 | 2022-12-20 | |
| Regulatory Post-Marketing Surveillance Study for Brolucizumab brolucizumab - Neovascular Age-related Macular Degeneration | Completed | Novartis Pharmaceuticals | 3369 | 2021-08-18 | 2026-11-06 | |
| Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration Brolucizumab - Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 52 | 2021-07-13 | 2025-09-26 |
| Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) brolucizumab - Age-related Macular Degeneration (AMD) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2021-05-31 | 2021-09-23 | |
| Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal Brolucizumab - Neovascular Age-related Macular Degeneration (nAMD) | Terminated | Novartis Pharmaceuticals | 81 | 2021-05-10 | 2025-03-25 | |
| A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections brolucizumab, ranibizumab, aflibercept - Neovascular Age-Related Macular Degeneration | Completed | Novartis Pharmaceuticals | 494 | 2021-02-23 | 2024-06-18 | |
| Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macula Edema | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2021-02-01 | 2021-03-04 | |
| A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration RTH258/Brolucizumab - Neovascular Age Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 210 | 2021-01-26 | 2024-10-09 |
| An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study brolucizumab - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 248 | 2020-12-16 | 2024-10-09 |
| Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration RTH258/Brolucizumab - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 295 | 2020-12-14 | 2024-11-07 |
Showing 20 of 42. Sign in to see all of them.
Macular Degeneration (16) · Vision Disorders (9) · Choroidal Neovascularization (8) · Wet Macular Degeneration (7) · Macular Edema (6) · Geographic Atrophy (5) · Diabetic Retinopathy (4) · Eye Diseases (4) · Retinal Diseases (4) · Retinal Degeneration (3) · Retinal Vein Occlusion (3) · Neurofibromatosis 2 (1) · Polypoidal Choroidal Vasculopathy (1) · Retinal Neovascularization (1) · Retinal Vasculitis (1)
Novartis Pharmaceuticals (34) · Alcon Research (3) · Berner Augenklinik (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1) · The University of Hong Kong (1) · Vista Klinik (1) · Yeungnam University College of Medicine (1)
United States (15) · Germany (8) · Puerto Rico (8) · Switzerland (8) · France (7) · Italy (7) · Canada (6) · Israel (6) · Japan (6) · South Korea (6) · Spain (6) · Australia (5) · China (5) · Czechia (5) · Taiwan (5)
Justus G. Garweg, Prof. Dr. med. (1) · Katja Hatz, PD Dr. med (1) · Nadia Zakaria, MD (1)
PMID 30986442, PMID 33207259, PMID 34968756, PMID 37343623, PMID 39033924, PMID 35188581, PMID 35301822, PMID 37971723, PMID 38360182, PMID 40833455, PMID 42024409, PMID 42082322, PMID 42492647
2019 (5), 2017 (2), 2018 (2), 2014 (1)